Breaking News Instant updates and real-time market news.

CURO

Curo Group

$23.09

0.09 (0.39%)

, HUYA

HUYA

$38.94

2.68 (7.39%)

08:30
06/14/18
06/14
08:30
06/14/18
08:30

Four new option listings and one option delisting on June 14th

New option listings for June 14th include CURO Group Holdings Corp (CURO), HUYA Inc (Class A ADS) (HUYA), Madrigal Pharmaceuticals (MDGL), and comScore Inc (SCOR). Option delistings effective June 14th include Ablynx NV (ADR) (ABLX).

CURO

Curo Group

$23.09

0.09 (0.39%)

HUYA

HUYA

$38.94

2.68 (7.39%)

MDGL

Madrigal Pharmaceuticals

$313.25

31.25 (11.08%)

SCOR

comScore

$24.64

-0.16 (-0.65%)

ABLX

Ablynx

$52.91

(0.00%)

CURO Curo Group
$23.09

0.09 (0.39%)

04/30/18
FBCO
04/30/18
NO CHANGE
Target $26
FBCO
Outperform
Curo Group price target raised to $26 from $21 at Credit Suisse
Credit Suisse analyst Moshe Orenbuch raised his price target for Curo Group to $26 from $21, citing a revenue beat, strong 2018 guidance, and tax reform that is likely a Q2 positive. The analyst reiterates an Outperform rating on the shares.
05/08/18
JEFF
05/08/18
NO CHANGE
Target $30
JEFF
Buy
Curo Group shares have 'meaningful upside,' says Jefferies
After hosting investor meetings with management, Jefferies analyst John Hecht remains favorable on Curo Group as one of his top picks in the alternative consumer finance space. With ongoing execution, Curo's discount to peers should disappear, Hecht tells investors in a research note. The analyst sees "meaningful upside" from current stock price levels and keeps a Buy rating on the shares with a $30 price target.
01/11/18
JANY
01/11/18
INITIATION
Target $19
JANY
Buy
Curo Group initiated with a Buy at Janney Capital
Janney Capital analyst John Rowan started Curo Group with a Buy rating $19 fair value estimate.
04/17/18
SPHN
04/17/18
NO CHANGE
Target $23
SPHN
Overweight
Curo Group named a new best idea at Stephens
Stephens analyst Vincent Caintic named Curo Group (CURO) his new best idea, replacing Alliance Data (ADS), as he believes Curo's online plus branch-based distribution model can power year-over-year EPS growth of 40% in 2019. The analyst noted that he still likes Alliance Data, but he thinks the shares will be muted until credit improves in the second half of the year. Caintic has an Overweight rating and $23 price target on Curo Group.
HUYA HUYA
$38.94

2.68 (7.39%)

06/13/18
NEED
06/13/18
INITIATION
Target $41
NEED
Buy
HUYA initiated with a Buy at Needham
Needham analyst Jinjin Qian initiated HUYA (HUYA) with a Buy rating and a price target of $41, citing the company's platform as a leader in live game streaming in China with 92.9M monthly active users. The analyst also points to "strong secular trends" in e-sports and live streaming, along with its close ties with YY (YY) and Tencent (TCEHY), supporting the company's position. Jinjin Qian calls HUYA a "solid" investment based on its "strong user metrics and scalable business model".
06/07/18
UBSW
06/07/18
INITIATION
UBSW
Neutral
HUYA initiated with a Neutral at UBS
MDGL Madrigal Pharmaceuticals
$313.25

31.25 (11.08%)

06/12/18
MAXM
06/12/18
NO CHANGE
Target $30
MAXM
Buy
Galmed price target raised to $30 from $14 at Maxim
Maxim analyst Jason McCarthy raised his outyear estimates for Aramchol and reduced his risk adjustment to 15% from 30% following the announcement of Galmed's (GLMD) Phase 2b data for Aramchol in NASH. Given the changes, he raised his price target on Galmed shares to $30 from $14, which he notes implies a market capitalization of $450M. That valuation may be viewed as "conservative" given the rise in valuations of others in the NASH space, including Madrigal (MDGL), which McCarthy said completed a Phase 2 study that was "smaller and shorter" than Galmed. He maintains a Buy rating on Galmed shares, which are up $13, or 185% to about $20 per share in afternoon trading.
06/07/18
EVER
06/07/18
NO CHANGE
Target $300
EVER
Outperform
Evercore ISI 'comfortable' with $300 price target on Madrigal after secondary
Evercore ISI analyst Josh Schimmer said he remains "comfortable" with his $300 price target on Madrigal Pharmaceuticals despite the stock trading off following the company's secondary offering of stock. After fielding calls from investors, Schimmer thinks a lack of catalysts "is probably the number one concern," as the company hopes to be able to start a Phase 3 NASH trial by year-end, which "probably means a 2-3 year void of news flow." Schimmer also listed long-term safety and efficacy and competitive dynamics as concerns voiced by investors he spoke with. He maintains an Outperform rating on Madrigal, which dropped over 10% in today's trading to about $281 per share.
06/05/18
MAXM
06/05/18
NO CHANGE
Target $14
MAXM
Buy
Chances of beta agonist success favors Viking Therapeutics, says Maxim
After Viking Therapeutics (VKTX) announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease, Maxim analyst Jason McCarthy said that given Viking's prior data and the data for Madrigal's (MDGL) MGL-3196, which is in the same class of Thyroid Hormone Receptor beta agonists, that he believes the probability of success favors Viking. He maintains a Buy rating and $14 price target on Viking shares.
06/14/18
HCWC
06/14/18
NO CHANGE
Target $15
HCWC
Buy
H.C. Wainwright says don't forget about Viking with Madrigal in play
After Bloomberg reported that Madrigal Pharmaceuticals (MDGL) is exploring a sale after receiving takeover interest, H.C. Wainwright analyst Joseph Pantginis tells investors to not forget about Viking Therapeutics (VKTX). The latter's potential treatment for non-alcoholic steatohepatitis, VK2809, could be even better than Madrigal's, Pantginis contends. The analyst believes that with Madrigal in play, it continues to bring "deserved focus to VK2809, which should garner significant business development interest as well." The analyst thinks VK2809 is "just starting to realize its underlying value from an investment standpoint." Citing the market potential for VK2809 and VK5211, the analyst highlights the value disconnect when comparing Madrigal's market capitalization of $4.8B with Viking's at $652M. Pantginis keeps a Buy rating on Viking Therapeutics with a $15 price target.
SCOR comScore
$24.64

-0.16 (-0.65%)

09/06/17
PIVT
09/06/17
NO CHANGE
Target $140
PIVT
Sell
Pivotal says Facebook ad reach claims look inflated
Pivotal Research analyst Brian Wieser noted that Australian trade publication AdNews found that Facebook (FB) claims to reach more 16-39 year-olds in the country than exist according to the country's census. His analysis of Facebook Ads Manager data compared to the U.S. consensus reveals a similar outcome. His talks with ad agency executives on this topic indicate that the gap between Facebook and census figures is not widely known, Wieser tells investors. The analyst, who keeps a Sell rating and $140 price target on Facebook, believes the primary winner of the social media giant's video expansion will be third party measurement firms, such as Nielsen (NLSN) and comScore (SCOR), he added.
09/12/17
NEED
09/12/17
NO CHANGE
NEED
comScore acquisition has become more likely, says Needham
After comScore announced that its CFO and seven members of its board were leaving and that two of its directors would work with Starboard to conduct a strategic review, Needham analyst Laura Martin thinks that a sale of the company has become more likely. However, she believes that it is "too early for fundamental investors to get involved" with the company and continues to refrain from publishing a rating on the stock.
06/12/18
06/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. InterDigital (IDCC) initiated with a Buy at Roth Capital. 2. Weight Watchers (WTW) initiated with an Overweight at JPMorgan and a Buy at DA Davidson. 3. Franklin Electric (FELE) initiated with a Neutral at DA Davidson. 4. ArQule (ARQL) initiated with an Outperform at Oppenheimer. 5. comScore (SCOR) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/11/18
LOOP
06/11/18
INITIATION
Target $32
LOOP
Buy
comScore initiated with a Buy at Loop Capital
Loop Capital analyst Alan Gould initiated comScore with a Buy rating and a price target of $32, saying the company's recent naming of a new CEO and re-listing on the Nasdaq marks a "new beginning". Gould notes that after several management changes over the past few years, comScore has started to show some revenue growth in the most recent quarter. The analyst adds that it will take some time for the new CEO to disclose and execute on his vision, but believes that there is "substantial upside" to comScore's current value.
ABLX Ablynx
$52.91

(0.00%)

01/29/18
BARD
01/29/18
DOWNGRADE
Target $56
BARD
Neutral
Ablynx downgraded to Neutral from Outperform at Baird
Sanofi (SNY) and Ablynx (ABLX) entered into a definitive agreement under which Sanofi will offer to acquire Ablynx.
01/08/18
DBAB
01/08/18
NO CHANGE
DBAB
Buy
Novo offer for Ablynx makes strategic sense, says Deutsche Bank
Deutsche Bank analyst Tim Race views Novo Nordisk's (NVO) acquisition offer for Ablynx (ABLX) as sensible, fitting with the stated company strategy and at a reasonable price. Depending on how discussions develop, the analyst would expect Novo to potentially raise its offer. Ablynx's caplacizumab could leverage Novo's readymade global haematology sales force with minimal additional cost, Race tells investors in a research note. The analyst keeps a Buy rating on Novo Nordisk.
11/20/17
11/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Innoviva (INVA) initiated with a Hold at Deutsche Bank. 2. National Vision (EYE) was initiated with an Overweight at Morgan Stanley, an Outperform at Wells Fargo, a Buy at Jefferies and Citi, as well as a Neutral at Goldman Sachs, UBS, and BofA/Merrill. 3. Ablynx (ABLX) was initiated with an Overweight at JPMorgan, an Outperform at Baird, and a Buy at Ladenburg. 4. Blue Apron (APRN) initiated with a Sector Weight at KeyBanc. 5. BP Midstream (BPMP) was initiated with an Overweight at JPMorgan, a Buy at UBS and Citi, an Equal Weight at Morgan Stanley and Barclays, as well as a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/18
BARD
01/09/18
NO CHANGE
Target $33
BARD
Outperform
Ablynx bid a floor for shares, other bids could follow, says Baird
Baird analyst Brian Skorney noted Novo Nordisk (NVO) went public with its $3.1B bid for Ablynx (ABLX). He believes the shares will trade above that level and that a new bid will emerge, although there are no other bidders yet. Skorney reiterated his Outperform rating and $33 price target on Ablynx shares.

TODAY'S FREE FLY STORIES

LGCY

Legacy Reserves

$4.78

-0.18 (-3.63%)

19:34
09/19/18
09/19
19:34
09/19/18
19:34
Initiation
Legacy Reserves initiated  »

Legacy Reserves initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMT

Core Molding

$7.75

-0.15 (-1.90%)

19:07
09/19/18
09/19
19:07
09/19/18
19:07
Hot Stocks
Core Molding names Eric Palomaki VP of Operations »

Core Molding Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMNI

Rimini Street

$6.92

0.33 (5.01%)

19:07
09/19/18
09/19
19:07
09/19/18
19:07
Hot Stocks
Rimini Street obtains Australian single touch payroll certification »

Rimini Street announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$37.30

0.2 (0.54%)

, LCI

Lannett

$4.85

0.15 (3.19%)

18:56
09/19/18
09/19
18:56
09/19/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Herman…

MLHR

Herman Miller

$37.30

0.2 (0.54%)

LCI

Lannett

$4.85

0.15 (3.19%)

AVP

Avon Products

$2.32

0.03 (1.31%)

NGD

New Gold

$1.10

0.03 (2.80%)

AMD

AMD

$31.20

-0.73 (-2.29%)

RHT

Red Hat

$143.38

0.59 (0.41%)

MTEM

Molecular Templates

$6.25

2.15 (52.44%)

CRSP

Crispr Therapeutics

$51.90

-1.27 (-2.39%)

KOS

Kosmos

$9.35

0.04 (0.43%)

VKTX

Viking Therapeutics

$19.64

0.17 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

  • 23

    Sep

  • 27

    Sep

  • 01

    Oct

  • 20

    Sep

  • 21

    Sep

  • 21

    Sep

  • 21

    Sep

LCI

Lannett

$4.85

0.15 (3.19%)

18:49
09/19/18
09/19
18:49
09/19/18
18:49
Hot Stocks
Breaking Hot Stocks news story on Lannett »

MintBroke International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.43

-0.86 (-1.01%)

18:43
09/19/18
09/19
18:43
09/19/18
18:43
Periodicals
Nike has sold out 61% more merchandise after Kaepernick ad, Reuters says »

Nike has sold out 61%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 20

    Sep

  • 25

    Sep

ADVM

Adverum Biotechnologies

$5.85

0.05 (0.86%)

18:38
09/19/18
09/19
18:38
09/19/18
18:38
Hot Stocks
Adverum Biotechnologies receives fast track designation for ADVM022 gene therapy »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

BTI

British American Tobacco

$46.87

-0.475 (-1.00%)

18:11
09/19/18
09/19
18:11
09/19/18
18:11
Hot Stocks
British American Tobacco CEO Durante to retire April 1, 2019 »

British American Tobacco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNY

Kearny Financial

$13.75

0.25 (1.85%)

18:02
09/19/18
09/19
18:02
09/19/18
18:02
Hot Stocks
Kearny Financial declares special cash dividend of 16c per share »

Kearny Financial has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$51.50

0.01 (0.02%)

18:00
09/19/18
09/19
18:00
09/19/18
18:00
Hot Stocks
Avista, Hydro One extend merger end date »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,926.27

-14.93 (-0.77%)

17:57
09/19/18
09/19
17:57
09/19/18
17:57
Periodicals
Amazon leaks new Alexa smart plug and a subwoofer, Verge says »

According to the Verge,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$163.06

2.75 (1.72%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Periodicals
Facebook sets up 'War Room' for safeguarding elections, NY Times says »

After Facebook gained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

RRTS

Roadrunner

$1.16

-0.065 (-5.33%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Syndicate
Roadrunner files S-1 for rights offering to existing holders »

Roadrunner announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$26.45

0.3 (1.15%)

17:35
09/19/18
09/19
17:35
09/19/18
17:35
Hot Stocks
Associated Banc-Corp announces $200M share repurchase program »

Associated's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLIN

Bridgeline Digital

$1.02

-0.01 (-0.98%)

17:32
09/19/18
09/19
17:32
09/19/18
17:32
Syndicate
Breaking Syndicate news story on Bridgeline Digital »

Bridgeline Digital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$1.10

0.03 (2.80%)

17:29
09/19/18
09/19
17:29
09/19/18
17:29
Hot Stocks
New Gold sells Mesquite Mine to Eqiunox Gold for $158M »

New Gold has entered into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

17:23
09/19/18
09/19
17:23
09/19/18
17:23
Periodicals
Trudeau wants to see more U.S. flexibility around NAFTA, Reuters says »

Canadian prime minister…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$339.26

-3.94 (-1.15%)

17:18
09/19/18
09/19
17:18
09/19/18
17:18
Hot Stocks
Lockheed Martin awarded $132.3M U.S. Navy contract modification »

Lockheed Martin Rotary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:17
09/19/18
09/19
17:17
09/19/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CFO sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ELAN

Elanco

$0.00

(0.00%)

17:14
09/19/18
09/19
17:14
09/19/18
17:14
Syndicate
Elanco 62.9M share IPO priced at $24.00 »

The IPO priced above its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MAMS

MAM Software

$7.67

0.02 (0.26%)

17:10
09/19/18
09/19
17:10
09/19/18
17:10
Hot Stocks
MAM Software announces $2M share repurchase program »

MAM Software Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:08
09/19/18
09/19
17:08
09/19/18
17:08
Hot Stocks
Coinbase names Brian Brooks chief legal officer »

Coinbase said in a blog…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

FNMA

Fannie Mae

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:07
09/19/18
09/19
17:07
09/19/18
17:07
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:06
09/19/18
09/19
17:06
09/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat says 24 of its 25…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:05
09/19/18
09/19
17:05
09/19/18
17:05
Hot Stocks
Red Hat Q2 backlog was up 20% on the year »

Deals over $1M were up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.